Frequently Asked Questions on Coronavirus Disease 2019 Vaccination for Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-Cell Recipients From the American Society for Transplantation and Cellular Therapy and the American Society of Hematology

Khawaja, Fareed; Papanicolaou, Genovefa A.; Dadwal, Sanjeet; Pergam, Steven A.; Wingard, John R.; Boghdadly, Zeinab El; Abidi, Maheen Z.; Waghmare, Alpana; Shahid, Zainab; Michaels, Laura; Hill, Joshua A.; Kamboj, Mini; Boeckh, Michael; Auletta, Jeffery J.; Chemaly, Roy F.

doi:10.1016/j.jtct.2022.10.010

Cited by 13 publications

(21 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results are in line with these reports and highlight the importance of a third mRNA vaccine dose in both responders and low responders to priming vaccination 6,9,13,14 . Importantly, a three‐dose vaccination schedule against COVID‐19 has been recommended by both the American Society of Transplantation and Cellular Therapy (ASTCT) and the European Society for Blood and Marrow Transplantation (EBMT) in patients after HCT and chimeric antigen receptor T‐cell therapy 15,16 …”

Section: Indroductionsupporting

confidence: 87%

“…6,9,13,14 Importantly, a three-dose vaccination schedule against COVID-19 has been recommended by both the American Society of Transplantation and Cellular Therapy (ASTCT) and the European Society for Blood and Marrow Transplantation (EBMT) in patients after HCT and chimeric antigen receptor T-cell therapy. 15,16 Our data point toward the positive effect of IST discontinuation on serological responses in low responders to two vaccine doses. In addition, we were able to show that in both allo-HCT recipients and healthy controls, a third vaccine dose led to a significant improvement of the humoral immune response.…”

mentioning

confidence: 70%

See 1 more Smart Citation

Antibody response to a third SARS‐CoV‐2 vaccine dose in recipients of an allogeneic haematopoietic cell transplantation

et al. 2022

View full text Add to dashboard Cite

Allogeneic haematopoietic cell transplantation (allo-HCT) recipients show impaired antibody (Ab) response to a standard two-dose vaccination against severe acute respiratory syndrome coronavirus-2 and currently a third dose is recommended as part of the primary vaccination regimen. By assessing Ab titres 1 month after a third mRNA vaccine dose in 74 allo-HCT recipients we show sufficient neutralisation activity in 77% of the patients. Discontinuation of immunosuppression before the third vaccine led to serological responses in 50% of low responders to two vaccinations. Identifying factors that might contribute to better vaccine responses in allo-HCT recipients is critical to optimise current vaccination strategies.

show abstract

Section: Indroductionsupporting

confidence: 87%

mentioning

confidence: 70%

Antibody response to a third SARS‐CoV‐2 vaccine dose in recipients of an allogeneic haematopoietic cell transplantation

et al. 2022

View full text Add to dashboard Cite

show abstract

“…European and United States transplant guidelines recommend COVID-19 vaccination as early as 3 months after transplantation or adoptive cellular therapy to prevent infection and severe disease [ 23 , 34 ]. These recommendations were based on limited data from few small sample size studies on COVID-19 vaccines and on previous clinical experience with other vaccine-preventable infections [ 23 , 51 ]. The Pfizer-BioNTech and Moderna messenger RNA COVID-19 vaccines are preferred for primary and booster vaccinations [ 51 ].…”

Section: Vaccination and Other Strategies For Preventing Rvismentioning

confidence: 99%

“…These recommendations were based on limited data from few small sample size studies on COVID-19 vaccines and on previous clinical experience with other vaccine-preventable infections [ 23 , 51 ]. The Pfizer-BioNTech and Moderna messenger RNA COVID-19 vaccines are preferred for primary and booster vaccinations [ 51 ]. COVID-19 vaccination should not be delayed in patients receiving IVIG [ 51 ].…”

Section: Vaccination and Other Strategies For Preventing Rvismentioning

confidence: 99%

“…The Pfizer-BioNTech and Moderna messenger RNA COVID-19 vaccines are preferred for primary and booster vaccinations [ 51 ]. COVID-19 vaccination should not be delayed in patients receiving IVIG [ 51 ]. Interestingly, the COVID-19 vaccines developed against earlier strains during the pandemic provided clinical protection despite decreased humoral responses after the emergence of highly mutated SARS-CoV-2 variants.…”

Section: Vaccination and Other Strategies For Preventing Rvismentioning

confidence: 99%

See 1 more Smart Citation

Respiratory Viral Infections in Recipients of Cellular Therapies: A Review of Incidence, Outcomes, Treatment, and Prevention

Dib

Ariza-Heredia

Spallone

et al. 2023

Open Forum Infectious Diseases

View full text Add to dashboard Cite

Respiratory viral infections (RVIs) are of major clinical importance in immunocompromised patients and represent a substantial cause of morbidity and mortality in patients with hematologic malignancies and those who have undergone hematopoietic cell transplantation. Similarly, patients receiving immunotherapy with CD19-targeted chimeric antigen receptor-modified T-cells, natural killer cells, and genetically modified T-cell receptors, are susceptible to RVIs and progression to lower respiratory tract infections. In adoptive cellular therapy recipients, this enhanced susceptibility to RVIs results from previous chemotherapy regimens such as lymphocyte-depleting chemotherapy conditioning regimens, underlying B-cell malignancies, immune related toxicities, and secondary prolonged, profound hypogammaglobulinemia. The aggregated risk factors for RVIs have both immediate and long-term consequences. This review summarizes the current literature on the pathogenesis, epidemiology, and clinical aspects of RVIs that are unique to recipients of adoptive cellular therapy, the preventative and therapeutic options for common RVIs, and appropriate infection control and preventative strategies.

show abstract

SARS-CoV-2 vaccination in the first year after allogeneic hematopoietic cell transplant: a prospective, multicentre, observational study

Hill¹,

Märtens²,

Young³

et al. 2023

eClinicalMedicine

View full text Add to dashboard Cite

Frequently Asked Questions on Coronavirus Disease 2019 Vaccination for Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-Cell Recipients From the American Society for Transplantation and Cellular Therapy and the American Society of Hematology

Cited by 13 publications

References 82 publications

Antibody response to a third SARS‐CoV‐2 vaccine dose in recipients of an allogeneic haematopoietic cell transplantation

Antibody response to a third SARS‐CoV‐2 vaccine dose in recipients of an allogeneic haematopoietic cell transplantation

Respiratory Viral Infections in Recipients of Cellular Therapies: A Review of Incidence, Outcomes, Treatment, and Prevention

SARS-CoV-2 vaccination in the first year after allogeneic hematopoietic cell transplant: a prospective, multicentre, observational study

Contact Info

Product

Resources

About